1. Aurinia will host a webcast on AUR200 Phase 1 results. 2. The event is scheduled for June 30, 2025, at 8:30 a.m. ET. 3. AUR200 targets unmet needs in autoimmune disease treatments. 4. LUPKYNIS® is Aurinia’s FDA-approved drug for lupus nephritis. 5. Company focuses on therapies with significant medical needs.
The announcement of study results could positively affect investor sentiment. Historical instances show stock boosts post-positively received drug development updates.
Webcast invites investor attention, raising interest in AUR200's potential. Successful Phase 1 results could enhance future market performance.
Long-term impact arises from potential drug approval and revenue generation. Past drug developments have shown sustained price increases over time.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.